DeepMed Research

European Organisation For Research & Treatment Of Cancer

🇬🇧United Kingdom

Country: 🇬🇧United Kingdom

Ownership: Private

Employees: -

Market Cap: -

Website: http://www.eortc.be

Clinical Trials

High-Dose or Low-Dose Interferon Alfa Compared With No Further Therapy Following Surgery in Treating Patients With Stage III Melanoma

Phase 3

Conditions: Melanoma (Skin)

First Posted Date: 2004-07-19

Last Posted Date: 2011-11-16

Lead Sponsor: European Organisation for Research and Treatment of Cancer - EORTC

Target Recruit Count: 1000

Registration Number: NCT00002763

Locations: 🇧🇪
Centre Hospitalier Notre Dame - Reine Fabiola, Charleroi, Belgium
🇧🇪
Universitair Ziekenhuis Gent, Ghent (Gent), Belgium
🇧🇪
U.Z. Gasthuisberg, Leuven, Belgium

and more 83 locations

Combination Chemotherapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Acute Myelogenous Leukemia

Phase 3

Conditions: Leukemia

First Posted Date: 2004-07-19

Last Posted Date: 2009-12-23

Lead Sponsor: European Organisation for Research and Treatment of Cancer - EORTC

Target Recruit Count: 1520

Registration Number: NCT00002549

Locations: 🇵🇹
Hospitais da Universidade de Coimbra (HUC), Coimbra, Portugal
🇨🇿
Institute of Hematology and Blood Transfusion, Prague, Czech Republic
🇧🇪
Algemeen Ziekenhuis Middelheim, Antwerp, Belgium

and more 72 locations

Prevention of Infection in Patients With Hematologic Cancer and Persistent Fever Caused by a Low White Blood Cell Count

Phase 3

Completed

Conditions: Bone Marrow Suppression
Fever, Sweats, and Hot Flashes
Infection
Leukemia
Lymphoma
Multiple Myeloma and Plasma Cell Neoplasm
Myelodysplastic Syndromes
Unspecified Adult Solid Tumor, Protocol Specific
Unspecified Childhood Solid Tumor, Protocol Specific

First Posted Date: 2004-07-16

Last Posted Date: 2012-09-24

Lead Sponsor: European Organisation for Research and Treatment of Cancer - EORTC

Target Recruit Count: 859

Registration Number: NCT00003805

Locations: 🇧🇪
Algemeen Ziekenhuis Middelheim, Antwerp, Belgium
🇨🇭
Universitaetsspital, Zurich, Switzerland
🇨🇭
Ospedale San Giovanni, Bellinzona, Switzerland

and more 25 locations

Combination Chemotherapy in Treating Patients With Advanced Non-small Cell Lung Cancer

Phase 3

Completed

Conditions: Lung Cancer

First Posted Date: 2004-07-13

Last Posted Date: 2012-03-06

Lead Sponsor: European Organisation for Research and Treatment of Cancer - EORTC

Target Recruit Count: 450

Registration Number: NCT00003589

Locations: 🇳🇱
Catharina Ziekenhuis, Eindhoven, Netherlands
🇳🇱
Ziekenhuis de Heel, Zaandam, Netherlands
🇨🇭
Ospedale San Giovanni, Bellinzona, Switzerland

and more 30 locations

Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed With Surgery

Phase 2

Conditions: Melanoma (Skin)

First Posted Date: 2004-07-12

Last Posted Date: 2015-02-10

Lead Sponsor: European Organisation for Research and Treatment of Cancer - EORTC

Target Recruit Count: 165

Registration Number: NCT00086866

Locations: 🇧🇪
Institut Jules Bordet, Brussels, Belgium
🇧🇪
Hopital Universitaire Erasme, Brussels, Belgium
🇬🇧
Christie Hospital NHS Trust, Manchester, England, United Kingdom

and more 18 locations

Erlotinib Compared With Temozolomide or Carmustine in Treating Patients With Recurrent Glioblastoma Multiforme

Phase 2

Completed

Conditions: Brain and Central Nervous System Tumors

First Posted Date: 2004-07-12

Last Posted Date: 2017-07-27

Lead Sponsor: European Organisation for Research and Treatment of Cancer - EORTC

Target Recruit Count: 110

Registration Number: NCT00086879

Locations: 🇫🇷
Centre Antoine Lacassagne, Nice, France
🇳🇱
Medisch Centrum Haaglanden, 's-Gravenhage, Netherlands
🇧🇪
U.Z. Gasthuisberg, Leuven, Belgium

and more 7 locations

Nitrocamptothecin in Treating Patients With Glioblastoma Multiforme

Phase 2

Completed

Conditions: Brain and Central Nervous System Tumors

First Posted Date: 2004-06-18

Last Posted Date: 2012-09-24

Lead Sponsor: European Organisation for Research and Treatment of Cancer - EORTC

Target Recruit Count: 17

Registration Number: NCT00005826

Locations: 🇮🇹
Azienda Ospedaliera di Padova, Padua, Italy
🇫🇷
Centre Eugene Marquis, Rennes, France
🇫🇷
Institut Gustave Roussy, Villejuif, France

and more 10 locations

MEN-10755 in Treating Adults With Recurrent or Refractory Solid Tumors

Phase 1

Completed

Conditions: Unspecified Adult Solid Tumor, Protocol Specific

First Posted Date: 2004-06-16

Last Posted Date: 2012-07-02

Lead Sponsor: European Organisation for Research and Treatment of Cancer - EORTC

Target Recruit Count: 5

Registration Number: NCT00003028

Locations: 🇫🇷
CHU de la Timone, Marseille, France
🇮🇹
Istituto Europeo Di Oncologia, Milano, Italy
🇮🇹
Istituto Nazionale per lo Studio e la Cura dei Tumori, Naples, Italy

and more 46 locations

Boron Neutron Capture Therapy Using Boronophenylalanine-Fructose Complex in Treating Patients With Metastatic Melanoma

Phase 2

Terminated

Conditions: Melanoma (Skin)

First Posted Date: 2004-06-11

Last Posted Date: 2012-07-18

Lead Sponsor: European Organisation for Research and Treatment of Cancer - EORTC

Target Recruit Count: 4

Registration Number: NCT00085059

Locations: 🇩🇪
Universitaetsklinikum Essen, Essen, Germany

Imatinib Mesylate in Treating Patients With Locally Advanced or Metastatic Dermatofibrosarcoma Protuberans or Giant Cell Fibroblastoma

Phase 2

Completed

Conditions: Sarcoma

First Posted Date: 2004-06-11

Last Posted Date: 2012-09-24

Lead Sponsor: European Organisation for Research and Treatment of Cancer - EORTC

Target Recruit Count: 17

Registration Number: NCT00085475

Locations: 🇳🇱
Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands
🇳🇱
Leiden University Medical Center, Leiden, Netherlands
🇬🇧
Christie Hospital NHS Trust, Manchester, England, United Kingdom

and more 4 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy